The newsletter discusses the battle between Eli Lilly and compounding pharmacies, Sanofi’s potential sale of Opella, Camp4 Therapeutics’ IPO, FDA approval for Genentech’s breast cancer drug, and an FDA advisory panel recommending a drug for Barth Syndrome. Senator Elizabeth Warren is urging the FTC to probe Novo’s Catalent acquisition. The podcast covers CRISPR, AI, and Denali-Sanofi partnership setbacks. Additionally, a study finds that nearly 60% of medical journal reviewers received substantial payments from industry. Sarepta’s gene therapy approval leads to a stock drop, Pfizer’s activist investor alert, and Gritstone’s bankruptcy filing are highlighted.
Source link
Denali x Sanofi, Genentech, crypto for CRISPR news
